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Abstract
A key characteristic of mushroom polysaccharides that elicit an immunomodulatory
response is that they are rich in β-glucans and low in α-glucans. In this study we analysed
nine commercially available preparations from three mushroom species, Reishi (Gano-
derma lucidum), Shiitake (Lentinula edodes) and Maitake (Grifola frondosa), for β- and α-
glucan content. Based on β- and α-glucan content we selected three extracts to combine
into a formula and evaluated the ability of the individual extracts and formula to impact on
the expression of cytokines IL-1α, IL-6, IL-10 and TNF-α in human macrophages with and
without LPS stimulation. The majority of mushroom extracts and the formula were found to
be highly potent immuno-stimulators possessing EC50 values lower than 100 μg/mL. Inter-
estingly the mushroom formula had lower EC50 values in TNF-α expression from LPS stimu-
lated macrophages compared to the individual extracts, suggesting a potential synergistic
effect of the mushroom formula. A response additivity graph and curve-shift analysis illus-
trated that indeed the mushroom formula exhibited an immuno-stimulatory synergistic effect
on the expression of the majority of cytokines evaluated in both LPS stimulated and non-
stimulated human macrophages, with IL-10 having an antagonistic response. This study
represents the first report of a synergistic immuno-modulatory response in human macro-
phages elicited from a mushroom formula rationally derived from β- and α-glucan content.
Introduction
Medicinal mushrooms possess a variety of bioactive compounds with immunomodulatory
activities, such as polysaccharides, polysaccharopeptides, phenolic compounds, proteins, lipid
components and terpenoids [1]. These immunomodulatory effects and subsequent potential
for therapeutic benefits are generating a renewed interest in the scientific investigation of
medicinal mushrooms, represented in the market by continual steady increases in worldwide
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sales [2, 3]. Mushroom polysaccharides, particularly β-D-glucans, are the focus of much of this
interest.
Approximately 80% of the mushroom cell wall consists of polysaccharides, with about half
of these being β-glucans. Glucans are the common name given to a group of chemically hetero-
geneous glucose (Glc) based polysaccharides that are classified based on the nature of the gly-
cosidic linkage as either α- or β-glucans. β-Glucans have a common structure comprising a
main chain of β-(1,3)- and/or β-(1,4)-D-Glc units, along with side chain Glc of varying lengths
and linkage [4]. What distinguishes fungal β-glucans is the presence of β-(1,6)-glucopyranosi-
dic side chains. β-Glucans, specifically branched (1,3:1,6) β-glucans of fungal origin are potent
immunological stimulators in humans. β-Glucans are not synthesized by humans, so these
compounds are recognized by the immune system as non-self molecules, inducing both innate
and adaptive immune responses [5], thus offering protection from attack by pathogenic
microbes and from harmful effects of environmental toxins and carcinogens.
There is extensive literature supporting the immune modulating effect of β-glucans in vivo.
The extent to which β-glucans are absorbed whole from the digestive tract is not fully resolved,
however it is likely that the principal site of interaction with immune cells is in gut-associated
lymphoid tissue. Both macrophages and dendritic cells present at gut mucosal surfaces have
glucan-binding surface receptors capable of activating signal transduction pathways that result
in modulation of immune responses [6–9].
A key characteristic of mushroom polysaccharides that elicit an immunomodulatory
response is that they are rich in β-glucans and low in α-glucans (β- and α-glucan content typi-
cally 10–40% and<5%, respectively [10]). In this study we analysed nine commercially avail-
able preparations from three mushroom species previously reported to stimulate the immune
system [5, 11], Reishi (Ganoderma lucidum), Shiitake (Lentinula edodes) and Maitake (Grifola
frondosa), for β- and α-glucan content. Based on their β- and α-glucan content we selected
three extracts to combine into a formula, with the immunostimulatory effect of the individual




Mushroom preparations, including extracts of fruiting bodies and preparations containing
mycelium as well as fruiting bodies (Table 1), were obtained from various standard commer-
cial suppliers and outlets as outlined in the International PCT Application No. PCT/AU2019/
050295 [12]. Briefly, these commercial mushroom extracts are prepared by the suppliers using
standard methods from whole dried mushrooms grown in China. Briefly, the ground mush-
room was extracted by repeated decoction (2–3hr at 80˚C) and the final solution centrifuged
to remove residues. The final extract was concentrated under vacuum at 55˚C and the concen-
trate spray-dried for 0.5–1 sec at 180˚C. Commercially available extracts generated in this way
were obtained from Nammex, Garuda International, Aloha Medicinals, Huisong Pharmaceu-
ticals, Zhejiang Fangge Pharmaceutical Co., Ltd., and Fungi Health.
Quantification of α- and β-glucans in mushroom extracts
α- and β-Glucan content was measured using the Megazyme kit K-YBGL (Megazyme Inc. IL.
USA), essentially as previously described [10].
Measurement of α-glucan (starch/glycogen). Approximately 100 mg (weighed accu-
rately) of the sample was added to a 20 × 125 mm screw capped tube, and the tube was tapped
to ensure that the entire sample fell to the bottom of the tube. A magnetic stirrer bar and 2.0
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mL of ice-cold 2 M KOH was added to each tube, and the tube contents were stirred using a
magnetic stirrer in an ice water bath for 20 min to dissolve the starch/glycogen. 1.2 M sodium
acetate buffer (pH 3.8; 8 mL) was added to each tube with mixing on a vortex stirrer. Amylo-
glucosidase (1630 U/mL) plus invertase (500 U/mL) (200μL) (from Megazyme kit) was imme-
diately added, the contents were mixed well, and the tubes were incubated at 40˚C for 30 min.
This solution (10.3 mL final volume) was centrifuged at 1500 rpm for 10 min and 0.1 mL of
the supernatant solutions was analysed for glucose with glucose oxidase/peroxidase reagent.
Measurement of total glucan. Approximately 100 mg (weighed accurately) of the sample
was added to a 20 × 125 mm screw capped tube, and the tube was tapped to ensure that the
entire sample fell to the bottom of the tube. A total of 2.0 mL of ice-cold 12 M sulfuric acid was
added to each tube, and the tubes were capped and stirred on a vortex mixer. Tubes were
placed in an ice–water bath and left for 2 h. During this time, the tube’s contents were vigor-
ously stirred (for 10–15 s) several times on a vortex mixer to ensure complete dissolution/dis-
persion of the sample. Water (2 × 5mL) was added in two portions to each tube, and the tubes
were capped and vigorously stirred on a vortex mixer for 10 s. The caps were loosened and the
tubes were placed in a hot-block heater (~100˚C). After 5 min, the caps were tightened and the
incubation was continued at 100˚C for 2 h. The tubes were cooled to room temperature, and
the caps were carefully loosened. 10 M KOH (6 mL) was added, and the tube contents were
mixed well. The contents of each tube were quantitatively transferred to 100 mL volumetric
flasks using 200 mM sodium acetate buffer (pH 5), and the volume was adjusted to 100 mL
with 200 mM sodium acetate buffer (pH 5). The contents were mixed thoroughly, and an ali-
quot (~10 mL) of the solution was centrifuged 1500rpm for 10 min in a bench centrifuge.
100 μL of the sample solution was incubated with 100 μL of a mixture of exo-1,3-β-glucanase
(20 U/mL) plus β-glucosidase (4 U/mL) at 40˚C for 60 min, and the glucose was determined
with GOPOD reagent as previously described (all of the reagents used were in the Megazyme
kit). Absorbance was measured at 510 nm. Concurrently, a 0.1 mL aliquot of glucose standard
solution (1 mg/mL), was incubated in quadruplicate (standard) with GOPOD reagent; also,
Table 1. Commercially available mushroom preparations used in this study.
Source Mushroom part Ref ID Drug-extract ratio
Reishi Fruiting body, mycelium, growth medium 1622 WM
Reishi Fruiting body 1628 4:1
Reishi Fruiting body, mycelium, growth medium 1639 WM
Reishi Fruiting body, mycelium 1631 66:1
Shiitake Fruiting body, mycelium, growth medium 1634 WM
Shiitake Fruiting body 1630 4:1
Shiitake Fruiting body 1633 4:1
Maitake Fruiting body 1629 4:1
Maitake Fruiting body, mycelium, growth medium 1635 WM
Reishi Fruiting body M18–1 16:1
Maitake Fruiting body M18–2 4:1
Shiitake Fruiting body M18–3 4:1
Formula: Fruiting bodies M18–13
Reishi M18–1 16:1 (10 parts)
Maitake M18–2 4:1 (33 parts)
Shiitake M18–3 4:1 (40 parts)
WM: Whole mushroom
https://doi.org/10.1371/journal.pone.0224740.t001
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0.1 mL of acetate buffer (200 mM, pH 5) was incubated with 3.0 mL of GOPOD reagent
(reagent blank).
Determination of β-glucan. The β-glucan content was determined by subtracting the α-
glucan content from the total glucan content.
Macrophage cell model
Human peripheral blood was obtained from a healthy human volunteer. The participant
received a written information sheet, and consent was obtained with a signed consent form.
The collection of human peripheral blood as outlined in Griffith University Human Research
Ethics Committee reference number 2016/713 was approved by the Griffith University
Human Research Ethics Committee. Isolation and differentiation of human macrophages was
performed using an adaptation of a previously described protocol [13]. Briefly, healthy human
peripheral blood was collected in lithium heparin vacuettes (Wishmed, NSW, AUS) and
inverted 5 times to prevent coagulation. Initially 15 mL of Histopaque1-1077 (Sigma-Aldrich
Co. LLC, MO, USA) solution at room temperature was added into two 50 mL centrifuge tubes
and 25 mL of peripheral blood was layered on top carefully without disturbing the Histopaque
layer. Both tubes were centrifuged at 400g without brake for 30 minutes at room temperature
to generate a density gradient. First the layer of plasma was aspirated out and discarded, subse-
quently the layer of PBMC as far into the Histopaque layer without disturbing the red blood
cells or neutrophils was collected and placed into a fresh tube. The PBMCs were then washed
with RPMI 1640 medium (Thermo Fisher Scientific, MA, USA) in a 1:1 solution and centri-
fuged for 10 minutes at 300g, 10˚C with the brake on. The resulting supernatant was discarded
and the RPMI wash step repeated with 10 mL of RMPI under the same conditions. Again,
supernatant was discarded and the pellet resuspended in culture medium consisting of RPMI
with 1% penicillin/streptomycin, 2.5 ng/mL M-CSF (macrophage colony-stimulating factor,
Thermo Fisher Scientific, MA, USA) and 10% NBCS (Newborn Calf Serum, Thermo Fisher
Scientific, MA, USA). Cells were incubated in Greiner 24 Well TC Plate (Interpath Services,
VIC, AUS) for 14 days at 37˚C with 5% CO2 at a density of 2x10
5 cells/mL to allow the cells to
adhere prior to any experiments being conducted. The behaviour and morphology of human
macrophages generated in this way were consistent with that previously published [13].
Cytokine expression analysis
Cells were treated with fresh media containing varying concentration of mushroom extracts or
formula (1, 10, 100, 1,000 μg/mL) with or without the addition of 1 μg/mL of LPS (Sigma-
Aldrich Co. LLC, MO, USA) and incubated for an additional 72 hours (24 hours for determi-
nation of TNF-α). Subsequently cell culture supernatant was collected and stored at -80˚C.
The cytokine level present in this supernatant was determined using ELISA-based assays sup-
plied by elisakit.com (VIC, AUS), with the concentration of cytokine present in the cell culture
supernatant (samples and controls) determined using a standard curve as described by the
manufacturer.
Statistical analysis
Data generated from the ELISA assays were used to produce a Nonlinear Regression Curve
performed using GraphPad Prism version 7.03 (Windows, GraphPad Software, CA, USA) to
determine the EC50/IC50 values of the three mushroom extracts and mushroom formula. The
parameters of the slope utilised was a variable slope with least squares (ordinary) fit and
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interpolate unknowns from a standard curve, generated with the following equation
Y ¼ Bottomþ ðTop   BottomÞ=ð1þ 10^ððLogEC
50
  XÞ �HillSlopeÞÞ:
A response additivity plot was generated to determine the additive effect of the mushroom
formula. The additive line was obtained by summing the cytokine expression levels that were
proportional to the percentage of extracts used in the mushroom formula. A response above
this additive line indicates a synergistic effect between the extracts and beneath the line an
antagonistic effect [14]. Another dose–effect curve approach, curve-shift analysis, was also
generated from the additive effect of the extracts on the individual dose–effect curves, an
example of two extracts can be expressed using the equation, Effect(x+y) = EX(x+xy) =
EY(yx+y) = EXY, where EX is the sum of the dose-effect from extract x plus the effect of extract
y at the same dose as x. This curve allows for identifying synergy in two ways, increase in
potency and/or an increase in efficacy relatively to the additive extract response [14].
Results and discussion
The determination of α- and β-glucan content in commercially available mushroom extracts
using the Megazyme method [10] found that six of the mushroom powders contain 10–20%
α-glucan (Table 2).
This high level of α-glucan is not naturally found in mushrooms [5] and likely indicates the
presence of non-mushroom glucans, such as those found in growth media (e.g. brown rice,
potato starch) and/or excipients (e.g. maltodextrin). As such the presence of glucans from
extraneous sources changes the overall glucan profile as revealed by the changes in β-glucan:
total glucan ratio (Table 2). The growth medium, for example, may contain β-glucan as well as
α-glucan (e.g. potato starch), resulting in relatively high levels of α-glucan as well as an
increase in β-glucan that is not derived from the mushroom. This means that it is not possible
to compare mushroom fruiting body products with mycelium-containing products on the
basis of the β-glucan content alone. More importantly, traditional use of these mushrooms was
based solely on the fruiting body, and it is a more recent innovation, through the advent of
bio-fermentation technologies, that full spectrum products are now appearing in the market.
Naturally, the presence of glucans from non-mushroom sources means the purity of the prod-
uct may be compromised. Based on the data shown in Tables 1 and 2 we generated a formula
Table 2. β-and α-Glucan composition of commercially available mushroom preparations used in this study.




Reishi 1622 38.6 12.6 51.2 3.1 0.75
Reishi 1628 38.0 1.1 39.1 34.5 0.97
Reishi 1639 31.0 17.8 48.8 1.7 0.64
Reishi 1631 21.4 13.9 35.3 1.5 0.61
Shiitake 1634 36.7 15.3 52.0 2.4 0.71
Shiitake 1630 12.3 1.2 13.5 10.0 0.91
Shiitake 1633 10.2 0.8 10.9 13.6 0.93
Maitake 1629 18.6 1.3 19.9 14.9 0.94
Maitake 1635 40.6 13.3 53.9 3.1 0.75
Reishi M18–1 17.7 3.2 20.9 5.5 0.85
Maitake M18–2 32.0 3.8 35.8 8.4 0.89
Shiitake M18–3 20.1 0.8 20.9 25.1 0.96
Formula M18–13 22.1 3.2 25.3 6.9 0.87
https://doi.org/10.1371/journal.pone.0224740.t002
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comprising Reishi, Shiitake and Maitake fruiting body extracts with the high β-glucan:α-glu-
can and β-glucan:total glucan ratios, with a view to preparing a formula that more effectively
expressed the immunomodulating activities reported with mushroom β-glucan. The composi-
tion of this formula was Reishi fruiting body extract (M18–1, 10 parts), Shiitake fruiting body
extract (M18–3, 40 parts) and Maitake fruiting body extract (M18–2, 33 parts), giving the
Maitake:Reishi:Shiitake ratio as 1.0:1.2:1.2 on a dry weight equivalent basis (Research from
this study has resulted in the development of a product released by Integria Healthcare. This
formula is marketed in Australia and New Zealand as MediHerb1Mushroom Forte
(AUSTL301609)). This combination was found to have a β-glucan:α-glucan ratio of 6.9 and a
β-glucan:total glucan ratio of 0.87. It has been reported that macrophages express cytokines in
response to stimulation by medicinal mushrooms [15]. We therefore assessed the ability of our
mushroom formula, and the individual extracts that comprise the formula, to impact the
expression of IL-1α, IL-6, TNF-α and IL-10 in human macrophages with and without LPS
stimulation by determining EC50 or IC50 values. The cytokines evaluated were chosen to cover
both pro- and anti-inflammatory cytokines and included those commonly used to monitor the
capacity of natural product preparations to elicit an immune response [16]. In addition to the
standard pro-inflammatory cytokines IL-6 and TNF-α, we also monitored the expression of
IL-1α over the more commonly evaluated IL-1β, as expression of IL-1α is known to induces
tumour regression [17].
In a similar way to that observed by others [18–21], the majority of individual mushroom
extracts induced dose-dependent increases in cytokine expression (S1–S4 Figs). Likewise, the
formula (M18–13) induced dose-dependent increases in cytokine expression in both non-LPS
and LPS treated macrophages (S1 Fig), indicating that the mushroom formula was potentially
acting as an immunostimulant. To further explore the immunostimulatory effects of the mush-
room formula and its component extracts, EC50 (concentration that gives half-maximal
response) and IC50 (concentration that inhibits response by half) values were determined by a
nonlinear regression variable slope. The majority of the EC50 values were<100 μg/mL
(Table 3), with the mushroom formula having EC50 values lower in the LPS stimulated macro-
phages compared to non-stimulated counterparts. Interestingly and unexpectedly, the EC50
values for the mushroom formula on LPS stimulated macrophages were lower in comparison
to the individual mushroom extracts that comprise the formula for TNF-α, and second lowest
for IL-6 and IL-10 (Table 3). These observations suggested a potential synergistic effect
between the individual components that make up the mushroom formula. As such further
analyses were performed to explore this significant phenomenon in more detail.
Table 3. EC50 and IC50 values associated with the effect of mushroom extracts and formula on cytokine expression in non-LPS (−) and LPS (+) stimulated human
macrophages.
EC50 or IC50 (μg/mL)
Shiitake (M18–3) Reishi (M18–1) Maitake (M18–2) Formula (M18–13)
−LPS +LPS −LPS +LPS −LPS +LPS −LPS +LPS
TNF-α 48.7 19.4 58.6 70.9 65.1 73.0 45.4 7.1
IL-1α 7.0 82.8 778.4 N.D. 14.4� 5.4� 434.1 177.7
IL-6 29.1 43.2 49.8 71.0 75.8 7.0 45.8 22.5
IL-10 20.1 34.9 31.0 78.0 5.1 6.3 25.6 16.0
Data derived from a nonlinear regression variable slope with interpolated unknowns from standard curve (S5–S8 Figs), EC50 determined from sample concentrations.
N.D. Not Determined as slope was unable to converge.
�Indicates IC50 values.
https://doi.org/10.1371/journal.pone.0224740.t003
Synergistic immuno-modulatory activity of a medicinal mushroom formulation
PLOS ONE | https://doi.org/10.1371/journal.pone.0224740 November 7, 2019 6 / 14
To determine the effect-based responses derived by the mushroom formula, a response
additivity graph was constructed for each cytokine investigated (Fig 1A–1H). This illustrates
the proportional effect on cytokine expression of the individual extracts comprising the mush-
room formula, in addition to the combination effect of the formula itself. Summing the effects
of the individual extracts generates the additive line. This line represents the level of expression
expected if the response derived from the mushroom formula was simply the sum of the indi-
vidual proportional responses of its components. However, the response additivity graph only
reflects a drug’s efficacy, not its potency. As seen in Fig 1A, TNF-α expression for the mush-
room formula in LPS stimulated macrophages was significantly greater (P< 0.05) than that of
the additive line, indicating a potential synergistic effect. This statistically significant synergis-
tic effect was also observed for the majority of cytokines in both LPS stimulated and non-LPS
human macrophages (Fig 1A, 1C–1F), except for TNF-α in non-stimulated macrophages and
Fig 1. Effect-based response additivity for cytokine expression induced by mushroom extracts and formula in LPS
stimulated and non-stimulated human macrophages. The expected additive effect (dashed line) represents the level
of expression expected if the response derived from the mushroom formula (M18–13) was simply the sum of the
individual responses of its components (M18–1, M18–2, M18–3). A response above the additive line indicates a
potential synergistic effect between the extracts and beneath the line a potential antagonistic effect. (A) TNF-α, (C) IL-
1α, (E) IL-6 and (G) IL10 expression in LPS stimulated macrophages; (B) TNF-α, (D) IL-1α, (F) IL-6 and (H) IL-10
expression in non-LPS stimulated macrophages. Mushroom preparation concentration 100 μg/mL. Results shown as
mean + SEM, statistics are Student’s t-test �P< 0.07, ��P< 0.05 and ���P< 0.01.
https://doi.org/10.1371/journal.pone.0224740.g001
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IL-10 in both LPS stimulated and non-LPS human macrophages (Fig 1B, 1G and 1H). Interest-
ingly, IL-10 showed a potential antagonistic effect where the response as a result of the mush-
room formula was less than the summed responses of the individual extracts (Fig 1G and 1H),
with statistical significance observed in non-stimulated macrophages (Fig 1H). It should be
noted that IL-10 expression as a result of treatment with the mushroom formula was still
greater than the IL-10 expression observed in the LPS stimulated macrophage control. Taken
together, our data suggests that the mushroom formula is inducing an immunostimulatory
response in a synergistic manner, by inducing the expression the pro-inflammatory IL-1α, IL-
6 and TNF-α, and reducing the expression of the anti-inflammatory IL-10 (compared to the
summed responses of the individual extracts).
A known limitation inherent to the response additivity design is the assumption that the
dose-response curves are linear with a zero intercept [14]. As such a curve-shift analysis was
subsequently performed (Fig 2), which allowed us to measure and confirm the putative syner-
gistic effect in two separate ways: an increase in potency and/or efficacy, indicated by a curve-
shift to the left and an increase in the slope of the curve relative to the combined effect of the
individual extract responses, respectively. As seen in Fig 2A for TNF-α, the mushroom for-
mula (solid black line) demonstrated an increase in both potency and efficacy over the additive
effects of the extracts (dashed black line), indicating that the mushroom formula evoked a
greater response at lower concentration as well as inducing an overall larger cytokine expres-
sion response than the sum effect produced by the individual extracts. Apart from IL-10, the
remaining curve-shift analyses (Fig 2) illustrated the formula’s synergistic effect with an
increase in efficacy for TNF-α, IL-6 and IL-1α. As well as being more potent at all concentra-
tions for TNF-α and IL-6 for non LPS treated macrophages (Fig 2A, 2B and 2F), increased
potency was also noted at higher concentrations (�100 μg/mL) for IL-1α and IL-6 for LPS
treated macrophages (Fig 2C, 2D and 2E). Interestingly, the formula had an antagonistic effect
on IL-10 cytokine expression in both non and LPS stimulated macrophages, with both potency
and efficacy being lower compared with the additive effects of the three extracts (Fig 2G and
2H).
The observed synergistic induction of pro-inflammatory cytokines together with the antag-
onistic effect on IL-10 by our mushroom formula could be explained by considering the inter-
play between pro- and anti-inflammatory cytokine expression during the innate immune
response. Macrophages are a main component of the innate immune system, this system acts
as the body’s first line of defence against infection [5]. The innate immune system utilises pat-
tern recognition receptors (PRRs) that recognise pathogen-associated molecular patterns
(PAMPs) to induce cytokine production within macrophages. The activation of macrophages
induces the secretion of proinflammatory cytokines such as TNF-α and IL-6, which are fol-
lowed by the secretion of anti-inflammatory cytokines. The pro-inflammatory cytokines have
protective roles in acute inflammatory responses, however an overexpression of these cyto-
kines can lead to chronic diseases [22–24]. The temporal release of anti-inflammatory cytokine
IL-10 is indicative of a feedback control mechanism that is used to prevent dysregulation of
the pro-inflammatory cytokines [24, 25]. Studies have shown that the addition of IL-6 to alter-
natively activated macrophages induced IL-10 expression [5], whereas in PBMC co-stimula-
tion with both TNF-α and Bt2cAMP also induced the expression of IL-10 [25].
As previously stated, to develop a formula that can effectively stimulate immunomodulating
activities, a mushroom formula was prepared using a combination of mushroom extracts with
high β-glucan:total glucan ratios. In order to further explore any potential correlation between
glucan content and immunomodulatory activity, coefficient of determination statistics were
calculated for cytokine expression levels versus percentage β-glucan, α-glucan, total glucan,
and β-glucan:total glucan ratio. Correlation (R2) statistics for the expression of IL-1α, IL-10
Synergistic immuno-modulatory activity of a medicinal mushroom formulation
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and TNF-α in both LPS stimulated and non-stimulated macrophages following exposure to
the mushroom extracts listed in Table 1 showed that the strongest positive correlation was
between β-glucan:total glucan ratio and IL-1α expression (R2 = 0.156) (S1 Table and S9–S12
Figs). This suggests that the increased expression of IL-1α in non-stimulated macrophages (S1
Table) may be correlated with the β-glucan:total glucan ratio. This is a particularly interesting
finding given that the expression of IL-1α is known to induces tumour regression [17]. Inter-
estingly the largest negative correlation was also observed between IL-1α in non-stimulated
macrophages and percentage α-glucan content (R2 = 0.229) present in the extract.
However, clearly the overall correlation strength is weak, indicating that the observed
immunomodulatory activity is not derived solely from the quantity of β-glucan or α-glucan,
but rather may be due to the nature of the β-glucan structures present. It is therefore critical
that future work explores the exact nature of the β-glucan structures that elicit specific immune
responses.
Fig 2. Curve-shift analysis for cytokine expression induced by mushroom extracts and formula in LPS stimulated
and non-stimulated human macrophages. The dose–effect curve for mushroom formula (M18–13) (▼ solid black
line) compared to the expected additive effect of the individual extract responses (◆ dashed black line), and the
individual mushroom extracts Shiitake (M18–2) (⚪ grey line), Reishi (M18–1) (□ grey line) and Maitake (M18–3) (�
grey line). (A) TNF-α, (C) IL-1α, (E) IL-6 and (G) IL10 expression in LPS stimulated macrophages; (B) TNF-α, (D) IL-
1α, (F) IL-6 and (H) IL-10 expression in non-LPS stimulated macrophages. Curve-shift analysis allows synergistic
effect to be measured in two separate ways, as an increase in potency and/or efficacy indicated by an increase in the
slope of the curve relative to the combined effect of the individual extract responses.
https://doi.org/10.1371/journal.pone.0224740.g002
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Conclusions
The concept of synergy is well established in the natural products field, with for example syn-
ergy reported between plant natural products for the prevention and/or treatment of cancer
[26, 27] and malaria [28], and between natural products and antibiotics for the treatment of
infectious disease [29]. Even though synergistic immunomodulatory effects between plant nat-
ural products have been reported [30, 31], to our knowledge this is the first report of synergis-
tic immunomodulatory activity between defined mushroom preparations. Specifically, this
study revealed the first observation of a synergistic effect of a mushroom formula on the
expression of the IL1-α, IL-6 and TNF-α, and an antagonistic effect on the expression of IL-10.
Further studies are required to more fully explore the synergistic immunomodulatory effect
observed by our mushroom formula, particularly determining the affinity and extent of
response induced by the interaction of well-defined, structurally elucidated mushroom β-glu-
cans with recognised pathogen-associated molecular patterns (PAMPs), and the pattern recog-
nition receptors (PRRs) present on macrophages.
Supporting information
S1 Fig. Triplicate repeats of the effect of a mushroom formula on cytokine expression on
LPS stimulated and non-stimulated human macrophages. Concentrations are represented
by log value and range from 1 to 1,000 μg/ml. Formula on LPS stimulated macrophages (black
solid line), Formula on non-LPS stimulated macrophages (dashed line), Control (no formula)
on LPS stimulated macrophages (horizontal dashed line), Control (no formula) on LPS stimu-
lated macrophages (dotted line). (A) TNF-α, (B) IL-1α, (C) IL-6, (D) IL-10.
(TIF)
S2 Fig. Triplicate repeats of Shiitake the effect of a on cytokine expression on LPS stimu-
lated and non-stimulated human macrophages. Concentrations are represented by log value
and range from 1 to 1,000 μg/ml. Shiitake on LPS stimulated macrophages (black solid line),
Shiitake on non-LPS stimulated macrophages (dashed line), Control (no Shiitake) on LPS
stimulated macrophages (horizontal dashed line), Control (no Shiitake) on LPS stimulated
macrophages (dotted line). (A) TNF-α, (B) IL-1α, (C) IL-6, (D) IL-10.
(TIF)
S3 Fig. Staggered Triplicate repeats on the effect of cytokine expression by varying Reishi
concentrations compared to control cytokine expression on ± LPS stimulated human mac-
rophages. Concentrations are represented by log value and range from 1 to 1,000 μg/ml. Reishi
on LPS stimulated macrophages (black solid line), Reishi on non-LPS stimulated macrophages
(dashed line), Control (no Reishi) on LPS stimulated macrophages (horizontal dashed line),
Control (no Reishi) on LPS stimulated macrophages (dotted line). (A) TNF-α, (B) IL-1α, (C)
IL-6, (D) IL-10.
(TIF)
S4 Fig. Staggered Triplicate repeats on the effect of cytokine expression by varying Maitake
concentrations compared to control cytokine expression on ± LPS stimulated human mac-
rophages. Concentrations are represented by log value and range from 1 to 1,000 μg/ml. Mai-
take on LPS stimulated macrophages (black solid line), Maitake on non-LPS stimulated
macrophages (dashed line), Control (no Maitake) on LPS stimulated macrophages (horizontal
dashed line), Control (no Maitake) on LPS stimulated macrophages (dotted line). (A) TNF-α,
(B) IL-1α, (C) IL-6, (D) IL-10.
(TIF)
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S5 Fig. Nonlinear regression EC50 curve of mushroom formula effect on cytokine expres-
sion in ± LPS stimulated human macrophages. Concentrations are represented by log value
and range from 1 to 1,000 μg/ml. Formula on LPS stimulated macrophages (black solid line),
Formula on non-LPS stimulated macrophages (dashed line). (A) TNF-α, (B) IL-1α, (C) IL-6,
(D) IL-10.
(TIF)
S6 Fig. Nonlinear regression EC50 curve of Shiitake effect on cytokine expression in ± LPS
stimulated human macrophages. Concentrations are represented by log value and range
from 1 to 1,000 μg/ml. Shiitake on LPS stimulated macrophages (black solid line), Shiitake on
non-LPS stimulated macrophages (dashed line). (A) TNF-α, (B) IL-1α, (C) IL-6, (D) IL-10.
(TIF)
S7 Fig. Nonlinear regression EC50 curve of Reishi effect on cytokine expression in ± LPS
stimulated human macrophages. Concentrations are represented by log value and range
from 1 to 1,000 μg/ml. Reishi on LPS stimulated macrophages (black solid line), Reishi on
non-LPS stimulated macrophages (dashed line). (A) TNF-α, (B) IL-1α, (C) IL-6, (D) IL-10.
(TIF)
S8 Fig. Nonlinear regression EC50 curve of Maitake effect on cytokine expression in ± LPS
stimulated human macrophages. Concentrations are represented by log value and range
from 1 to 1,000 μg/ml. Maitake on LPS stimulated macrophages (black solid line), Maitake on
non-LPS stimulated macrophages (dashed line). (A) TNF-α, (B) IL-1α, (C) IL-6, (D) IL-10.
(TIF)
S9 Fig. Coefficient of determination statistics calculated for IL-1α in LPS non-stimulated
macrophages. Expression levels versus percentage β-glucan (a), α-glucan (b), total glucan (c),
β-glucan: total glucan ratio (d) on LPS non-stimulated macrophages following exposure to the
mushroom extracts listed in Table 1.
(TIF)
S10 Fig. Coefficient of determination statistics calculated for IL-1α in LPS stimulated mac-
rophages. Expression levels versus percentage β-glucan (a), α-glucan (b), total glucan (c), β-
glucan: total glucan ratio (d) on LPS stimulated macrophages following exposure to the mush-
room extracts listed in Table 1.
(TIF)
S11 Fig. Coefficient of determination statistics calculated for IL-10 in LPS non-stimulated
macrophages. Expression levels versus percentage β-glucan (a), α-glucan (b), total glucan (c),
β-glucan: total glucan ratio (d) on LPS non-stimulated macrophages following exposure to the
mushroom extracts listed in Table 1.
(TIF)
S12 Fig. Coefficient of determination statistics calculated for IL-10 in LPS stimulated mac-
rophages. Expression levels versus percentage β-glucan (a), α-glucan (b), total glucan (c), β-
glucan: total glucan ratio (d) on LPS stimulated macrophages following exposure to the mush-
room extracts listed in Table 1.
(TIF)
S13 Fig. Coefficient of determination statistics calculated for TNF-α in LPS non-stimu-
lated macrophages. Expression levels versus percentage β-glucan (a), α-glucan (b), total glu-
can (c), β-glucan: total glucan ratio (d) on LPS non-stimulated macrophages following
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exposure to the mushroom extracts listed in Table 1.
(TIF)
S14 Fig. Coefficient of determination statistics calculated for TNF-α in LPS stimulated
macrophages. Expression levels versus percentage β-glucan (a), α-glucan (b), total glucan (c),
β-glucan: total glucan ratio (d) on LPS stimulated macrophages following exposure to the
mushroom extracts listed in Table 1.
(TIF)
S1 Data. Excel file containing raw data associated with figures (including supporting infor-
mation figures) presented in this study.
(XLS)
S1 Table. Summary of coefficient of determination. R2 values for β-glucan, α-glucan, total
glucan, and β-glucan: total glucan composition data between the mushroom preparations
listed in Table 1 and cytokine expression in human macrophages ± LPS stimulation.
(TIF)
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